The ‘propofol infusion syndrome’: the facts, their interpretation and implications for patient care
- 1 December 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Anaesthesiology
- Vol. 23 (12), 990-998
- https://doi.org/10.1017/s0265021506001281
Abstract
AstraZeneca (the manufacturer of Diprivan™) presents its review of the history of the so-called ‘propofol infusion syndrome’, highlighting the difficulties in analysing the incomplete information available. Theories as to its causality are presented and discussed; these include mitochondrial toxicity, mitochondrial defects, impaired tissue oxygenation and carbohydrate deficiency. A review of published and confidential safety data is presented and discussed; it concludes that the major risk factors for its development appear to be poor oxygen delivery, sepsis, serious cerebral injury and high propofol dosage. In some reports an increasing lipaemia was noted and was likely to be due to a failure of hepatic lipid regulation, possibly related to poor oxygenation and/or possibly a lack of glucose. In some cases an increasing lipaemia was the first indication of impending ‘propofol infusion syndrome’ onset and it should not be viewed as a benign sign. The lipaemia can lead to sequestration of propofol into the lipid phase, leading to lowered free propofol levels and apparent insensitivity to propofol. In conclusion AstraZeneca advocates good haemodynamic and oxygen delivery management, adequate glucose provision, adherence to recommended propofol dosing regimes together with active management of lipaemias to both prevent and treat ‘propofol infusion syndrome’.Keywords
This publication has 27 references indexed in Scilit:
- Continuous Propofol Infusion in 142 Critically Ill ChildrenPEDIATRICS, 2002
- Propofol and Midazolam in the Treatment of Refractory Status EpilepticusEpilepsia, 2001
- Long-term propofol infusion and cardiac failure in adult head-injured patientsThe Lancet, 2001
- Cardiac Involvement in Patients With Acute Neurologic DiseaseArchives of Internal Medicine, 2000
- Propofol-infusion syndrome in childrenThe Lancet, 1999
- Propofol infusion syndrome in childrenPediatric Anesthesia, 1998
- A comparison of propofol and other sedative use in paediatric intensive care in the United KingdomPediatric Anesthesia, 1997
- Propofol infusion in children.BMJ, 1992
- Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports.BMJ, 1992
- REDUCTION OF STRESS/ CATECHOLAMINE-INDUCED CARDIAC NECROSIS BY BETA1-SELECTIVE BLOCKADEThe Lancet, 1987